Still Bullish On HCV, Idenix Also Plans To Focus On Oncology, Other Infectious Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
New Chief Scientific Officer Jacques Dumas says the clinical-stage firm intends to leverage its expertise in nucleoside discovery to create drug candidates for cancer and other infectious diseases. Concurrent with its drug development in hepatitis C, Idenix plans to address these other indications with the help of partners.
You may also be interested in...
Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.